Contineum Therapeutics (CTNM) Operating Expenses (2023 - 2024)
Historic Operating Expenses for Contineum Therapeutics (CTNM) over the last 2 years, with Q4 2024 value amounting to $17.0 million.
- Contineum Therapeutics' Operating Expenses rose 7617.82% to $17.0 million in Q4 2024 from the same period last year, while for Sep 2025 it was $17.0 million, marking a year-over-year decrease of 6083.31%. This contributed to the annual value of $50.9 million for FY2024, which is 5002.8% up from last year.
- According to the latest figures from Q4 2024, Contineum Therapeutics' Operating Expenses is $17.0 million, which was up 7617.82% from $13.0 million recorded in Q3 2024.
- Contineum Therapeutics' Operating Expenses' 5-year high stood at $17.0 million during Q4 2024, with a 5-year trough of $5.1 million in Q1 2023.